Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,733 | -29,362 | -19,841 | -13,491 | -6,903 |
| Depreciation Amortization | 15 | 127 | 94 | 63 | 32 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -1,213 |
| Other Working Capital | -1,298 | 1,288 | -709 | -1,787 | -1,421 |
| Other Operating Activity | 1,147 | 2,134 | 1,628 | 1,134 | 1,614 |
| Operating Cash Flow | $-10,869 | $-25,813 | $-18,828 | $-14,081 | $-7,891 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -5,425 | N/A | N/A | N/A | N/A |
| PPE Investments | -42 | -61 | -32 | N/A | N/A |
| Investing Cash Flow | $-5,467 | $-61 | $-32 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -985 | -985 | -986 | -201 |
| Common Stock Issued | 88 | 35,934 | 129,767 | 36,037 | 1,076 |
| Other Financing Activity | 0 | 93,453 | 0 | 0 | 0 |
| Financing Cash Flow | $88 | $128,402 | $128,782 | $35,051 | $875 |
| Beginning Cash Position | 119,166 | 16,638 | 16,638 | 16,638 | 16,638 |
| End Cash Position | 102,918 | 119,166 | 126,560 | 37,608 | 9,622 |
| Net Cash Flow | $-16,248 | $102,528 | $109,922 | $20,970 | $-7,016 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,869 | -25,813 | -18,828 | -14,081 | -7,891 |
| Capital Expenditure | -42 | -61 | -32 | N/A | N/A |
| Free Cash Flow | -10,911 | -25,874 | -18,860 | -14,081 | -7,891 |